Amoxicillin-Clavulanate Dosing Guidelines for Adults with Acute Bacterial Infections

Introduction to Amoxicillin-Clavulanate Therapy

The American Academy of Otolaryngology-Head and Neck Surgery recommends using 2000 mg/125 mg twice daily (or 90 mg/kg/day of amoxicillin component) when risk factors for resistant organisms are present, such as antibiotic use within the past 4-6 weeks, age >65 years, recent hospitalization, immunocompromised status, geographic regions with high rates of penicillin-nonsusceptible Streptococcus pneumoniae, close contact with daycare facilities, or smoking/household smoker 1, 2
The Infectious Diseases Society of America suggests that amoxicillin-clavulanate is preferred over amoxicillin alone in adults due to better coverage of beta-lactamase-producing organisms, although the evidence is weaker than in children 3

The American Academy of Otolaryngology-Head and Neck Surgery identifies risk factors for resistant organisms, including antibiotic use within the past 4-6 weeks, age >65 years, recent hospitalization, immunocompromised status, geographic regions with high rates of penicillin-nonsusceptible Streptococcus pneumoniae, close contact with daycare facilities, and smoking/household smoker 1, 2
Indicators of moderate-to-severe infection include moderate to severe symptoms of ABRS, fever ≥39°C (102°F) with systemic toxicity, frontal or sphenoidal sinusitis, history of recurrent ABRS, and comorbid conditions (diabetes, chronic cardiac/hepatic/renal disease) 1, 2

The American Academy of Otolaryngology-Head and Neck Surgery recommends a clinical decision algorithm, where patients with penicillin allergy should use doxycycline or respiratory fluoroquinolone (levofloxacin/moxifloxacin) instead, and those with non-Type I hypersensitivity should consider clindamycin plus third-generation cephalosporin 1, 2
For patients without allergy, the dose should be determined based on risk stratification, with low-risk patients receiving 875/125 mg twice daily and high-risk patients receiving 2000/125 mg twice daily 1, 2, 4
The treatment duration is typically 5-7 days for uncomplicated acute bacterial rhinosinusitis (ABRS) in adults 3

Macrolides and trimethoprim-sulfamethoxazole should NOT be used due to high resistance rates (>40% for macrolides, 50% for TMP-SMX against S. pneumoniae) 1, 2
The 2000/125 mg formulation uses a pharmacokinetically enhanced, modified-release mechanism specifically designed for resistant pathogens 5

The American Academy of Otolaryngology-Head and Neck Surgery recommends using a high-dose regimen of 2000 mg/125 mg twice daily to eradicate penicillin-resistant S. pneumoniae with MICs up to 4-8 mg/L, which is critical for achieving therapeutic amoxicillin levels for approximately 49% of the 12-hour dosing interval at an MIC of 4 mcg/mL 6

The Infectious Diseases Society of America (IDSA) recommends amoxicillin-clavulanate as the preferred first-line antibiotic for acute bacterial rhinosinusitis (ABRS) in adults, based on theoretical concerns about resistance, with a number needed to treat of 18 for one patient to benefit and a number needed to harm from antibiotic adverse effects of 8 7, 8
The IDSA guidelines suggest that ABRS should only be treated with antibiotics when patients meet specific clinical criteria, including persistent symptoms for more than 10 days without clinical improvement, severe symptoms, or a "double sickening" pattern 7, 8
The European guidelines support using amoxicillin-clavulanate as monotherapy or in combination with macrolides for hospitalized patients with community-acquired pneumonia (CAP) without risk factors for Pseudomonas, with a recommended dose of 875 mg/125 mg twice daily for 7-10 days 9
The French guidelines recommend amoxicillin-clavulanate for acute bronchiolitis in pediatric patients only in specific high-risk situations, including high fever persisting for more than 3 days, associated purulent acute otitis media, or pneumonia or atelectasis confirmed by chest X-ray 10